30th Apr 2014 10:34
LONDON (Alliance News) - Oxford Pharmascience Group PLC said Wednesday it has appointed Quotient Clinical to undertake its early clinical development programme for its OXP003 Safestat product proof of concept study.
The specialty pharmaceutical firm said it has appointed the company to undertake the study as it progresses towards clinical proof of concept study with the OXP003 Safestat atorvastatin product.
Oxford Pharmascience redevelops medicines to make them better, safer and easier to take. The firm said it has reviewed its proposed initial clinical development programme for the Safestat atorvastatin product with the Medicines and Healthcare Products Regulatory Agency using the Scientific Advice Scheme and has appointed Quotient Clinical to conduct the proof of concept study with this drug delivery technology.
The company has completed initial formulation development of Safestat, its colon targeted drug delivery formulation of atorvastatin, and is proceeding towards clinical proof of concept testing which it said aims to demonstrate the colon delivery of atorvastatin will reduce Cytochrome P450 metabolism and hence increase efficacy and improve safety of atorvastatin through reduced inter and intra-patient variability and lower risk of drug-drug interactions with medications that are CYP450 inhibitors.
Oxford Pharmascience shares were trading 0.02% lower at 5.124 pence per share Wednesday morning.
By Alice Attwood; [email protected]; @AliceAtAlliance
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Pharmascience Group